Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III Study of M610101 in Atopic Dermatitis
jRCT2031220567Phase 3Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ruxolitinib cream in atopic dermatitis (AD) (3 arms), sponsored by Maruho Co., Ltd. Primary endpoint: IGA 0/1 response at week 8. Started Jan 2023; status: completed.
02
Drugs
ruxolitinib cream
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031220567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220567.